Everything's Special At US FDA: Priority NDA/BLA Filings Surge
Executive Summary
The FY 2018 PDUFA performance report also indicates that applications with standard assessments fell compared to long-term averages.
You may also be interested in...
US FDA Priority Review Voucher Fee Continues Drop In FY 2020
Sponsors will pay 12% less to redeem a voucher in FY 2020, which is charged on top of the traditional PDUFA user fee.
US FDA Struggles To Meet Goals As Drug Sponsors' Meeting Requests Rise
The FDA did not expect to meet many FY 2018 goals for on-time scheduling of formal PDUFA meetings or issuing written responses in lieu of meetings.
FDA's Biosimilars Meeting Management Should Improve After Reorg In New Drug Office
US FDA met more biosimilar user fee program meeting performance goals in FY 2018 compared to prior year but still fell short in scheduling for three of five types of meetings. Office of New Drugs reorganization, once completed, should address some logistical scheduling issues.